Australia markets open in 2 hours 21 minutes

Chimeric Therapeutics Limited (CHM.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0210-0.0010 (-4.55%)
At close: 04:10PM AEST
Full screen
Previous close0.0220
Open0.0210
Bid0.0210 x 24502200
Ask0.0220 x 16334300
Day's range0.0210 - 0.0210
52-week range0.0210 - 0.0470
Volume819,578
Avg. volume2,390,765
Market cap18.841M
Beta (5Y monthly)1.68
PE ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings date29 Feb 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS

    Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers.

  • GlobeNewswire

    Chimeric Therapeutics To Attend BIO International Convention

    SYDNEY, Australia and NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX: CHM) (“Chimeric Therapeutics”, “Chimeric” or the “Company”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is please to announce that Jennifer Chow, Chief Executive Officer and Managing Director, will present at the Biotechnology Innovation Organization (BIO) International Convention, taking place June 5-8, 2023 at the Boston Convention and Exhibition Center in Boston,

  • GlobeNewswire

    Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial

    New CHM 1101 (CLXT CAR T) multi-center clinical trial activated at Sarah Cannon Research Institute (SCRI) in Austin, TexasEnrolment now open to patients with recurrent and/or progressive glioblastoma multiforme (GBM), the most common and most deadly primary brain cancer SYDNEY, Australia, June 04, 2023 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), the only clinical stage cell therapy company on the ASX, is pleased to announce activation of a Phase 1B clinical